Two Merck Medicines Recommended For Approval In The European Union

Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE? (nicotinic acid/ laropiprant, MSD) 1000 mg/20 mg tablets for patients with dyslipidemia or primary hypercholesterolemia. Separately, the U.S.

More: continued here

Filed under: Cholesterol on May 15th, 2008